- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial
May 8th 2025, 12:00pm
Unpacking Key Data from ASH 2024
Panelists discuss how the updated results from Arm 8 of the Epcore NHL-2 trial on Fixed-Duration Epcoritamab + R-Mini-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) ineligible for full-dose R-CHOP may influence treatment selection by offering a potentially effective alternative for this patient population
Ultra-Low PSA Response With Darolutamide/ADT Correlates With Better Outcomes in mHSPC
May 7th 2025, 12:00pm
American Urological Association Annual Meeting
Ultra-low PSA responses were linked with prolonged rPFS and delayed times to mCRPC and PSA progression for patients with mHSPC treated with darolutamide.
Botensilimab Plus Balstilimab Elicits Durable Responses in Treatment-Refractory HCC
May 6th 2025, 12:00pm
Phase 1 data support further exploration of botensilimab plus balstilimab in patients with hepatocellular carcinoma.
Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial
May 1st 2025, 12:05pm
Unpacking Key Data from ASH 2024
Panelists discuss how iopofosine I 131 demonstrated efficacy and safety in previously treated patients with Waldenstrom macroglobulinemia (WM) in the CLOVER-WaM study, potentially influencing the broader treatment paradigm by introducing a novel targeted radiopharmaceutical approach and shaping future research toward optimizing combination therapies and long-term outcomes.
Oncology Experts Highlight the Key Data and Top Abstracts From AUA 2025
May 1st 2025, 12:00pm
American Urological Association Annual Meeting
Experts revisit the most intriguing abstracts and data they saw presented at the 2025 American Urological Association Annual Meeting.
Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL
May 1st 2025, 12:00pm
Unpacking Key Data from ASH 2024
Panelists discuss how the 5-year follow-up data from the ZUMA-5 trial demonstrate sustained efficacy and durable remission of axicabtagene ciloleucel in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), potentially signaling a paradigm shift toward considering chimeric antigen receptor (CAR) T-cell therapy as a more prominent early-line treatment option for these challenging lymphoma subtypes.
Adjuvant Aumolertinib Boosts DFS in Stage II-IIIB, EGFR-Mutated NSCLC
April 30th 2025, 8:36pm
Adjuvant aumolertinib improved disease-free survival in complete resected stage II to IIIB non–small cell lung cancer harboring EGFR mutations.
Adjuvant Trifluridine/Tipiracil Benefit is Limited to Select Subgroups in MRD+ CRC
April 30th 2025, 8:15pm
Trifluridine/tipiracil showed a favorable safety profile and numerically improved DFS vs placebo in MRD-positive CRC.
Adagrasib Yields Early Efficacy in STK11- and KRAS G12C–Mutant NSCLC
April 30th 2025, 6:48pm
First-line adagrasib monotherapy demonstrated preliminary efficacy and tolerability in patients with SK11- and KRAS G12C–mutant NSCLC.
Neoadjuvant Botensilimab Plus Balstilimab Is Active, Safe Regardless of Mismatch Repair Status in Solid Tumors
April 30th 2025, 5:25pm
Botensilimab and balstilimab proved active and safe as neoadjuvant therapy in patients with mismatch repair–deficient and –proficient solid tumors.
Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC
April 30th 2025, 1:30am
Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.
Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer
April 29th 2025, 11:51pm
Avutometinib plus abemaciclib and fulvestrant had manageable toxicity in CDK4/6-resistant, HR+/HER2– metastatic breast cancer.
SYN818 Shows Favorable Safety Profile in Locally Advanced or Metastatic Solid Tumors
April 29th 2025, 11:08pm
A phase 1b trial examining SYN818 plus olaparib in patients with solid tumors will be conducted in the second half of 2025.
Runimotamab Plus Trastuzumab Is Active and Tolerable in HER2+ Breast Cancer
April 29th 2025, 10:38pm
Runimotamab in combination with trastuzumab led to clinical activity and tolerability vs runimotamab alone in HER2-positive breast cancer.
Dr Sobh on the Effects of NSD2 Overexpression in Multiple Myeloma
April 29th 2025, 10:10pm
Amin Sobh, PhD, discusses findings from a study investigating the immune surveillance–modulating capabilities of NSD2 overexpression in multiple myeloma.
Invikafusp Alfa Generates Clinical Activity in Checkpoint Inhibitor–Resistant Solid Tumors
April 29th 2025, 9:41pm
Invikafusp alfa was active in unresectable, locally advanced or metastatic solid tumors resistant to immune checkpoint inhibitors.
Sequencing Regorafenib After Fruquintinib Improves OS in mCRC
April 29th 2025, 8:34pm
Initial fruquintinib followed by regorafenib extended OS vs the reverse sequence of the agents in patients with metastatic colorectal cancer.
ICT01 Plus Azacitidine and Venetoclax Shows Early Evidence of Antitumor Activity in AML
April 29th 2025, 8:21pm
A low dose of ICT01 added to combination therapy with azacitidine and venetoclax proved active and safe as frontline therapy in patients with AML.
Padeliporfin VTP Therapy Yields Complete Responses With Manageable Safety in Low-Grade, Upper Tract Urothelial Cancer
April 29th 2025, 8:17pm
American Urological Association Annual Meeting
Padeliporfin vascular targeted photodynamic therapy was safe and generated responses in low-grade, upper tract urothelial cancer.
Prospective, Real-World Study Highlights Feasibility of Outpatient Robotic Partial Nephrectomy in Renal Tumors
April 29th 2025, 8:05pm
American Urological Association Annual Meeting
A high proportion of patients with renal tumors were discharged on the same day after receiving robotic partial nephrectomy.